And in November 2024, our licensed partner, Cutia Therapeutics received regulatory approval to market Amzeeq in China, which triggered a $1 million milestone payment to Journey. Continuing the ...

And in November 2024, our licensed partner, Cutia Therapeutics, received regulatory approval to market Amzeeq in China, which triggered a $1 million milestone payment to Journey. Continuing the ...

2024 reflects a $1.0 million milestone payment pursuant to Journey’s license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) that became payable to us upon Cutia receiving marketing ...

2024 reflects a $1.0 million milestone payment pursuant to Journey’s license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) that became payable to us upon Cutia receiving marketing approval ...

Trailing total returns as of 03/04/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) ...

At close: 28 March at 4:08:08 pm GMT+8 ...

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...